CROMOPTIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cromoptic, and when can generic versions of Cromoptic launch?
Cromoptic is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in CROMOPTIC is cromolyn sodium. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cromoptic
A generic version of CROMOPTIC was approved as cromolyn sodium by SANDOZ on June 16th, 1999.
Summary for CROMOPTIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Patent Applications: | 4,783 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CROMOPTIC at DailyMed |
US Patents and Regulatory Information for CROMOPTIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | CROMOPTIC | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 075088-001 | Apr 27, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |